Although SGLT2 inhibitors reduce the number of cardiovascular deaths and hospitalizations for HF in patients with HFpEF with or without diabetes, it remains unclear (38, 39) as to whether SGLT2 inhibitors added to the standard HF regime reduce the readmission rate. The gene discussed is SLC5A2; the disease is hydrops fetalis.